Finance

Lists
TORNTPHARM:NSE
Torrent Pharmaceuticals Ltd
4 772,50 INR
-0,57%
(-27,50) 1D
1-окт., 15:30:00 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for TORNTPHARM...
Open
4 800,00 INR
High
4 810,50 INR
Low
4 717,30 INR
Mkt. cap
1,61 трлн
Avg. vol.
331,85 миң
Volume
357,70 миң
Dividend
0,80%
Quarterly dividend
9,50 INR
Ex-dividend date
2026-ж., 29-май
P/E ratio
76,24
52-wk high
5 250,00 INR
52-wk low
3 480,60 INR
EPS
62,60 INR
Shares outstanding
170,00 млн
No. of employees
18 миң
Open
4 800,00 INR
High
4 810,50 INR
Low
4 717,30 INR
Mkt. cap
1,61 трлн
Avg. vol.
331,85 миң
Volume
357,70 миң
Dividend
0,80%
Quarterly dividend
9,50 INR
Ex-dividend date
2026-ж., 29-май
P/E ratio
76,24
52-wk high
5 250,00 INR
52-wk low
3 480,60 INR
EPS
62,60 INR
Shares outstanding
170,00 млн
No. of employees
18 миң
News stories
From web sources and news partners
Profile
Torrent Pharmaceuticals Ltd, d/b/a Torrent Pharma, is an Indian multinational pharmaceutical company, part of the Torrent Group and headquartered in Ahmedabad. It was promoted by U. N. Mehta, initially as Trinity Laboratories Ltd, and was later renamed Torrent Pharmaceuticals Ltd. Torrent Pharmaceuticals operates in more than 40 countries with over 2,000 product registrations globally. Torrent Pharma is active in the therapeutic areas of cardiovascular, central nervous system, gastro-intestinal, diabetology, anti-infective and pain management segments. It also has a presence in therapeutic segments of nephrology, oncology, gynecology, respiratory and pediatrics. Wikipedia
About Torrent Pharmaceuticals Ltd
CEO-
Employees18,3 миң
Founded1959
HeadquartersAhmedabad, Гажарат, Индия
SectorPharmaceutical industry
Last report
2026-ж., 30-июл.
Fiscal period
Q1 2027
EPS / Est. (INR)
15,30 INR / 16,20 INR
-5,55%miss
Revenue / Est. (INR)
49,21 млд / 47,29 млд
+4,07%beat
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
33,02 млд
33,03 млд
41,97 млд
49,21 млд
Cost of goods sold
8,00 млд
7,99 млд
10,15 млд
11,63 млд
Cost of revenue
8,00 млд
7,99 млд
10,15 млд
11,63 млд
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6,27 млд
6,51 млд
8,48 млд
8,93 млд
Operating expense
16,23 млд
16,22 млд
23,34 млд
26,87 млд
Total operating expenses
24,23 млд
24,21 млд
33,49 млд
38,50 млд
Operating income
8,79 млд
8,82 млд
8,48 млд
10,71 млд
Other non operating income
-270,00 млн
-130,00 млн
794,40 млн
-120,00 млн
EBT including unusual items
7,91 млд
8,14 млд
5,29 млд
7,33 млд
EBT excluding unusual items
8,04 млд
8,24 млд
5,47 млд
7,54 млд
Income tax expense
2,00 млд
1,79 млд
1,65 млд
1,67 млд
Effective tax rate
25,28%
21,99%
31,18%
22,78%
Other operating expenses
7,92 млд
7,65 млд
9,78 млд
12,01 млд
Net income
5,91 млд
6,35 млд
3,89 млд
5,66 млд
Net profit margin
17,90%
19,22%
9,28%
11,50%
Earnings per share
17,75
19,00
12,85
15,30
Interest and investment income
-
-
384,30 млн
-
Interest expense
-480,00 млн
-450,00 млн
-2,36 млд
-3,05 млд
Net interest expenses
-480,00 млн
-450,00 млн
-1,97 млд
-3,05 млд
Depreciation and amortization charges
2,04 млд
2,06 млд
5,08 млд
5,93 млд
EBITDA
10,82 млд
10,69 млд
11,12 млд
13,35 млд
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google колдонмолору